Acellular Pertussis Completed Phase 2 Trials for Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)

IndicationStatusPhase
DBCOND0031302 (Acellular Pertussis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01171989Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DosePrevention